The Chinese Pharmacopoeia is the national statutory basis of guiding the development, production, operation, use, supervision, management of drug, etc.
In 1953, China promulgated the first edition of the Chinese Pharmacopoeia, and has maintained the pace of updating one version every five years since then. The Chinese Pharmacopoeia 2020 Edition was implemented since December 30, 2020, which overall improved quality standards for Chinese drugs, thus making a great difference on pharmaceutical manufacturers focused on APIs, excipients and packaging materials. For overseas companies concerned about the Chinese market, it is also necessary to keep abreast of:
What are the changes and features of the latest version of the Pharmacopoeia?
What are the remaining differences between the revised Chinese Pharmacopoeia and international drug standards?
To help international enterprises better understand the Chinese Pharmacopoeia 2020 Edition, Baipharm invited Ms. Qiaofeng Tao, Vice President of Zhejiang Institute for Food and Drug Control, to share her rich expertise and experience.